Press Releases

First Previous Next End

September 27, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31st SITC Annual Meeting

Provectus today announced that the Society for Immunotherapy of Cancer has accepted an abstract for a poster presentation related to the use of PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, in the treatment of pancreatic cancer.

September 8, 2016

Provectus Biopharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference

Provectus today announced that it will present at Rodman & Renshaw's 18th Annual Global Investment Conference.

August 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Provectus today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each.

August 25, 2016

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million

Provectus today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock.

August 24, 2016

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

August 23, 2016

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

Provectus today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

August 9, 2016

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended June 30, 2016.

August 1, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress

Provectus today announced that a poster presentation titled "Intralesional rose bengal for stage III and IV melanoma" is to be presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in Copenhagen, Denmark.

July 20, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 second quarter business update conference call on Wednesday, August 10, 2016 at 4 pm Eastern Daylight Time.

July 18, 2016

Provectus Biopharmaceuticals Receives Patent Allowance for Use of Halogenated Xanthenes in Pharmaceutical Compositions and as Medicaments

Provectus today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The allowed claims cover use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

July 14, 2016

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus today announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. In addition, the Company is opening a Sydney office in New South Wales.

July 13, 2016

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Provectus today announced that data on PV-10 as a treatment for melanoma was presented June 30, 2016 at the 6th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

July 12, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress

Provectus today announced that the European Society for Medical Oncology's Scientific Committee has accepted an abstract for a poster presentation detailing the use of PV-10 as a treatment for stage III and IV melanoma as part of ESMO's 2016 Congress.

June 9, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online

Provectus today announced that the poster presented at the Annual Meeting of the American Society of Clinical Oncology is now available online.

June 7, 2016

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology

Provectus today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology.

June 7, 2016

Provectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA

Provectus today announced that it will present at the 2016 BIO International Convention in San Francisco, CA.

June 1, 2016

Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page

Provectus announced today the launch of its newly redesigned website at www.Provectusbio.com as well as the company's official Facebook page at www.facebook.com/Provectusbio.

May 19, 2016

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma

Provectus today announced the availability of an abstract titled "A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma" that has been published in conjunction with the annual meeting of the American Society of Clinical Oncology ("ASCO") being held in Chicago June 3-7, 2016.

May 19, 2016

Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting

Provectus today announced the availability online of an abstract titled "Intralesional rose bengal for treatment of melanoma" to be presented as a poster at the annual meeting of the American Society of Clinical Oncology ("ASCO") being held in Chicago June 3-7, 2016.

May 13, 2016

Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10's Immuno-Ablative Mechanism of Action

Provectus today announced that an article has been published detailing the immuno-ablative mechanism of action of PV-10, the Company's novel investigational drug for cancer.

First Previous Next End